Novartis said it will begin selling the first biosimilar drug in the U.S. after an appeals court denied Amgen’s request to block the Swiss drug maker’s sale of its copycat version of blockbuster remedy Neupogen.
from WSJ.com: US Business http://ift.tt/1NOLGVy
via IFTTT
No comments:
Post a Comment